A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
← catalyst calendarNCT07258836 · readout ≤ 164 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
41estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-22 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neoplasms
- Healthy
Intervention
- Drug: LY4214835
Primary outcomes
what the primary-completion date above is the date OFNumber of Incidence of Adverse Events (AEs)
measured Baseline Through Day 3
Number of Radiation Absorbed Dose Estimates in Body Organs to Obtain Whole-body Effective Dose
measured Baseline Through Day 3
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed